{"id":"W2045626426","doi":"10.1097/jto.0b013e31824166c1","title":"Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Hazard ratio; Oncology; Lung cancer; Pharmacogenetics; Odds ratio; Placebo; Epidermal growth factor receptor; Confidence interval; Gastroenterology; Genotype; Cancer; Pathology; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00307232,0.001623682,0.002457386,0.0005242234,0.0004622783,0.001099631,0.0008276504,0.001845651,0.006637688],"category_scores_gemma":[0.004326746,0.0006060682,0.002868412,0.000447243,0.001024666,0.0009509515,0.0004247364,0.002383683,0.0008798719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007582061,"about_ca_system_score_gemma":0.0009810373,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003966894,"about_ca_topic_score_gemma":0.0007674822,"domain_scores_codex":[0.997624,0.001572379,0.0001172633,0.0003295726,0.0001585695,0.0001983323],"domain_scores_gemma":[0.9983702,0.000620485,0.0004469017,0.0002340689,0.0000867303,0.0002415988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9668404,0.00339122,0.001543417,0.0003232112,0.003646239,0.00006463181,0.00003168906,0.0009346927,0.005739975,0.0003667118,0.0007616705,0.01635602],"study_design_scores_gemma":[0.8859116,0.09124649,0.00910743,0.00003938999,0.006814508,0.0001624506,0.00003035966,0.001686206,0.001557573,0.001260287,0.002138119,0.00004555708],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853061,0.003663225,0.001995145,0.001230801,0.0003263605,0.001832474,0.002326714,0.0001666515,0.003152409],"genre_scores_gemma":[0.9934226,0.0007753648,0.001311453,0.0006284631,0.0001554824,0.0008788071,0.001271578,0.00003379198,0.001522477],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006637688,"threshold_uncertainty_score":0.02220529,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03442907352970298,"score_gpt":0.5197147873300292,"score_spread":0.4852857138003262,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}